Full-Time
Confirmed live in the last 24 hours
Develops targeted cancer therapies using synthetic lethality
Expert
Boston, MA, USA
You match the following Tango Therapeutics's candidate preferences
Employers are more likely to interview you if you match these preferences:
Tango Therapeutics develops targeted cancer treatments using the principle of synthetic lethality, which allows them to design drugs that kill cancer cells while leaving healthy cells unharmed. Their approach focuses on the interaction between genes, where the loss of both genes leads to cell death, but the loss of just one does not. This method enables them to create more effective therapies for cancer patients. Tango operates in the oncology market, primarily serving healthcare providers and pharmaceutical companies. They collaborate with larger pharmaceutical firms, like Gilead Sciences, to co-develop new therapies, which helps them secure funding and speed up the development process. Their goal is to bring next-generation targeted immunotherapies to market, supported by a strong team and strategic partnerships.
Company Size
51-200
Company Stage
IPO
Total Funding
$341.4M
Headquarters
Cambridge, Massachusetts
Founded
2017
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that it will discontinue development of its TNG348 program. “Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further development of this molecule due to liver toxicity experienced by patients in the trial. While disappointing, we believe this is the right decision given the data at hand,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “We will focus resources and capital on our existing portfolio, particularly our PRMT5 program. We remain committed to and confident in our ability to deliver a comprehensive clinical update on TNG908 and TNG462 in the second half of this year.”
BOSTON--(BUSINESS WIRE)-- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.“In 2023, we made meaningful progress developing precision oncology treatments and now have four ongoing phase 1/2 clinical trials. These treatments have the potential to reach people with a wide range of cancers, including those with MTAP-deleted solid tumors, STK11 loss-of-function mutations, BRCA 1/2 mutations and other DNA damage repair defects. To support the advancement of our broad clinical portfolio, we expanded our management team, adding members with expertise in regulatory affairs and clinical development,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “We are off to a strong start in 2024, marked by dosing the first patient in the phase 1/2 clinical trial for TNG348, receiving Orphan Drug Designation from the U.S. FDA for TNG462 and strengthening our cash position
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in March.Leerink Partners 2024 Global Biopharma ConferenceDate: Tuesday, March 12, 2024Time: 3:00 PM ETLocation: Miami, FLBarclays 26th Annual Global Healthcare ConferenceDate: Wednesday, March 13, 2024Time: 9:30 AM ETLocation: Miami, FLA live webcast of the presentations will be available under the "Events & Presentations" tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcasts will be archived on the Company's website for 90 days following the presentation.About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023 in Boston, Massachusetts.Abstracts accepted for poster presentationTitle: MTA-cooperative PRMT5 inhibitors selectively modulate RNA splicing in MTAP-deleted cancer cells across histologies. Poster #: B018. Presenter: Matthew R. Tonini, Senior Scientist, Tango Therapeutics
Medivir´s Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study. .